Emerging nanocarriers as advanced delivery tools for the treatment of leukemia.

Abstract

The most common type of blood cancer, leukemia, presents global therapeutic challenges like heterogeneity regarding age, sex, race, and a multiple pool of oncogenes and their complex network. In the last few years, nanotechnology has become the potential solution in leukemic resistance, chemotherapeutic failure, and disease-remission risk. Interestingly, the nanocarriers alone sometimes cannot overcome leukemia's obstacles, which demands a more advanced flagship in the nanocarrier segment like modification of the nanocarrier system, external stimuli for synergistic antileukemic effect, etc. This review has highlighted the need for emerging nanocarriers like exosome-like vesicles, nanodiamonds, nanoflower, etc. and biomimetic nanocarriers that reach the bone marrow niche. Notably, the role of nanoparticle-based vaccines in a disease-remission-free life and novel technology for nanocarrier delivery (microfluidics and plasmonic nanobubbles) have been discussed. This review also focuses on the clinical transition barriers of nanocarriers from the research laboratory. The continual research on novel nanocarriers and integration of new technologies to deliver the nanocarriers in the right way is paving the path for enhanced selectivity and efficacy in leukemia. The promising results in precise drug delivery and leukemic cell destruction are showing its great clinical prospects.